Arvinas Announces Data Presentations from the Vepdegestrant ( ARV-471 ) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium ( SABCS )

GlobeNewswire
2025.11.24 13:04
portai
I'm PortAI, I can summarize articles.

NEW HAVEN, Conn., Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Arvinas, Inc. ( Nasdaq: ARVN ) , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant ( ARV-471 ) have been accepted for ...

Source: GlobeNewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer